摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(fluoromethyl)-1,3-oxazole-4-carboxylic acid | 1310351-11-1

中文名称
——
中文别名
——
英文名称
2-(fluoromethyl)-1,3-oxazole-4-carboxylic acid
英文别名
2-(Fluoromethyl)oxazole-4-carboxylic acid
2-(fluoromethyl)-1,3-oxazole-4-carboxylic acid化学式
CAS
1310351-11-1
化学式
C5H4FNO3
mdl
——
分子量
145.09
InChiKey
CKNXBVMLMZSEOM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    281.0±20.0 °C(Predicted)
  • 密度:
    1.454±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    63.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES<br/>[FR] AMIDES 2-AMINO-6-MÉTHYL-4,4A,5,6-TÉTRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL-1,3-THIAZOL-4-YLE
    申请人:PFIZER
    公开号:WO2015155626A1
    公开(公告)日:2015-10-15
    The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    本发明涉及所披露的化合物、互变异构体和药学上可接受的盐,其中所述化合物具有式(I)的结构,变量R1如规范中所定义。还披露了相应的药物组合物、治疗方法、合成方法和中间体。
  • [EN] N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES<br/>[FR] N-[2-(2-AMINO-6,6-DISUBSTITUÉS-4,4A,5,6-TÉTRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL)-1,3-THIAZOL-4-YL]AMIDES
    申请人:PFIZER
    公开号:WO2017051276A1
    公开(公告)日:2017-03-30
    The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐,其中所述化合物具有式(I)的结构,变量R1、R2和R3如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
  • 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES
    申请人:Banner David
    公开号:US20110144097A1
    公开(公告)日:2011-06-16
    The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    本发明涉及具有BACE1和/或BACE2抑制活性的2-基-5,5-二-5,6-二氢-4H-[1,3]噁唑-4-基)苯基]-酰胺的化合物(式I),其制造,含有它们的药物组合物以及它们用作治疗活性物质的用途。本发明的活性化合物在治疗和/或预防阿尔茨海默病和2型糖尿病等方面具有用途。
  • Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES
    申请人:F. Hoffmann-La Roche AG
    公开号:US09067926B2
    公开(公告)日:2015-06-30
    Provided herein is a compound of formula I: as wells as a pharmaceutical composition, a process of making and a method of using a compound of formula I. The compounds of formula I are BACE1 inhibitors useful for the treatement of, for example, Alzheimer's Disease.
    本文提供了I式化合物,以及一种制药组合物、制药过程和使用I式化合物的方法。I式化合物是BACE1抑制剂,可用于治疗例如阿尔茨海默病等疾病。
  • FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES
    申请人:F. Hoffmann-La Roche AG
    公开号:US20150031690A1
    公开(公告)日:2015-01-29
    The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    本发明提供了一种具有BACE1抑制活性的化合物(I)的制备方法,包括含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防例如阿尔茨海默病等疾病方面具有用途。
查看更多